View Clinical Trial (Medical Research Study)

A Study Of PF-04449913 In Select Hematologic Malignancies Or With Dasatinib In Chronic Myeloid Leukemia (CML) - NCT00953758-92037(Clinical Trial 461039)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  La Jolla
State:  
CA
Zip Code: 92037
Conditions: Hematologic Neoplasms
Purpose: This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies. Part two of the study will examine the effect of this inhibitor in combination with dasatinib In Chronic Myeloid Leukemia.
Study summary:
Criteria: Inclusion Criteria: - Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies. They may be newly diagnosed and previously untreated, but not eligible for standard treatment options, or for whom standard therapies are not anticipated to result in a durable response. - ECOG performance status 0 to 2 - Adequate organ function Exclusion Criteria: - Patients with active CNS disease - Patient with active malignancy with the exception of basal cell carcinoma, non melanoma skin cancer, carcinoma in situ cervical or skin cancer - Active GVHD other than Grade 1 skin involvement - Known malabsorption syndrome - Patient has an active, life threatening or clinically significant uncontrolled systemic infection
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: February 17, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.